Evidence map›Paper›PMID 37926548›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Glomerular Microangiopathy-like Nephropathy Caused by Hyperthyroidism.

Yuri Katayama, Naoki Sawa, Shigekazu Kurihara, Daisuke Ikuma, Yuki Oba, Akinari Sekine, Masayuki Yamanouchi, Eiko Hasegawa, Tatsuya Suwabe, Takehiko Wada and 5 more

Abstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuri KatayamaDepartment of Nephrology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.
Naoki SawaDepartment of Nephrology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.
Shigekazu KuriharaDepartment of Nephrology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.
Daisuke IkumaDepartment of Nephrology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.
Yuki ObaDepartment of Nephrology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.
Akinari SekineDepartment of Nephrology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.
Masayuki YamanouchiDepartment of Nephrology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.
Eiko HasegawaDepartment of Nephrology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.
Tatsuya SuwabeDepartment of Nephrology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.
Takehiko WadaDepartment of Nephrology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.
Kei KonoDepartment of Pathology, Toranomon Hospital, Japan.
Keiichi KinowakiDepartment of Pathology, Toranomon Hospital, Japan.
Kenichi OhashiDepartment of Pathology, Toranomon Hospital, Japan.
Yoshiki TsuchiyaDepartment of Urology, Tokatsu Hospital, Japan.
Yoshifumi UbaraDepartment of Nephrology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 49-year-old Japanese woman was admitted to our hospital with weight loss of 15 kg, nephrotic-range proteinuria (4.5 g/g.Cre), and hematuria over a 6-month period. She had received two doses of the coronavirus disease 2019 (COVID-19) vaccine one year before the onset of the disease, after which the estimated glomerular filtration rate increased. Laboratory tests and other tests led to a diagnosis of hyperthyroidism, and a kidney biopsy showed thrombotic microangiopathy-like glomerular microangiopathy comprising mainly glomerular endothelial cell damage. Thiamazole (30 mg) was started for the hyperthyroidism. Three months later, the thyroid function normalized, and two months later, the proteinuria and hematuria disappeared, suggesting that COVID-19 vaccination and these events were related.

Indexed as

HyperthyroidismThrombotic MicroangiopathiesAntithyroid AgentsCOVID-19COVID-19 VaccinesFemaleHematuriaHumansKidney DiseasesKidney GlomerulusMethimazoleMiddle AgedAntithyroid AgentsCOVID-19 VaccinesMethimazoleCOVID-19 vaccinationglomerular microangiopathyhyperthyroidismtamoxifenTMA-like renal disease

Identifiers

PMID37926548
PMCPMC11239258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.